Home
    Registration
    Accommodation
    Topics
    Contact
Home
Welcome Note
Committees
List of Faculty
Speaker Guidelines
Timetable
Scientific Program
Anterior Segment Section
Glaucoma Section
Retina Section
Neuro-Ophthalmology
Trauma
Uveitis
New Plays in the Game
Symposia
Poster Presentations
Group A
Group B
Poster Presentation Guidelines
Registration
Invitation Letter
Accommodation
InterContinental Budapest
Sponsorship & Exhibition
Sponsors
Exhibitors
CME
General Information
Local Agent
Italian Agent
Before you travel...
About Budapest
Endorsements
Partners
Previous Congresses
COPHy 2010
COPHy 2011
COPHy 2012

  Symposia Print


Friday, April 5, 2013

 
Management of Glaucoma in 2013 - is it preservative free?  
Symposium (not for CME)
(Supported by Allergan)
10:30-11:45
Chairperson: A. Heijl, Sweden 
 
10:30-10:35
Welcome
A. Hejil, Sweden
 10:35-10:50
Efficacy is still the key in management of glaucoma
A. Heijl, Sweden
 
10:50-11:05
Preservative free is the key
A. Bron, France
    
11:05-11:15
Who and how to find the patients suitable for preservative treatment?
F. Cordiero, UK
 
11:15-11:35
Preserative free glaucoma management - unmet need? Pros and cons
I. Stalmans, Belgium
  
11:35-11:45
Close
A. Heijl, Sweden
 
      
 
New Horizons in the Treatment of VMT and Macular Hole
Luncheon Symposium (not for CME)
(Supported by Alcon)
12:00-13:00
Chairperson: A.J. Augustin, Germany
12:00-12:05

Welcome
A.J. Augustin, Germany
12:05-12:15
 
Vitreomacular Traction and Macular Holes
M. De Smet, The Netherlands
12:15-12:30
Vitreoretinal Interface Separation
 W. Mieler, USA
12:30-12:40
New Horizons in Retina Surgery: 27+ and vitrectomy probe of 7500cpm
S. Rizzo
, Italy
12:40-12:55
Questions, discussion with panel and audience, and wrap-up
A.J. Augustin, Germany
   
 
Long-term anti-VEGF therapy: Reflections on recent evidence
Symposium (not for CME)
(Supported by Novartis)
15:30-16:30
Chairperson: S. Kelly, UK
15:30-15:35
Chair's welcome and introduction
S. Kelly, UK
15:35-13:45
Seeing the whole picture: Special safety considerations in retinal diseases
S. Kelly, UK
13:45-13:55
Under the microscope: Comparing curent anti-VEGF agents
T. Lai, Hong Kong
13:55-16:10
Focus on the evidence: What do the trial data say?
N. Bressler, USA & T. Lai, Hong Kong
16:10-16:20
Looking through the window: The real world of clinical practice
S. Kelly, UK
 
16:20-16:30
Closing statement and final questions
S. Kelly, UK
  

Saturday, April 6, 2013
 
Innovation in Wet AMD Treatment
Symposium (not for CME)
(Supported by Bayer Healthcare)
10:30-11:45
Chairperson: A. Loewenstein, Israel
10:30-10:45
 
 
An introduction to EYLEA® (aflibercept) for wAMD
A. Loewenstein
, Israel
10:45-10:55
Question and answer session
 
10:55-11:10
Initiating EYLEA® treatment
S. Michels
, Switzerland
11:10-11:20
Question and answer session
11:20-11:35
Establishing treatment with EYLEA®
N. Bressler
, USA
 
11:35-11:45
Question and answer session
  
 
Management of ME in 2013
Symposium (not for CME)
(Supported by Allergan)
12:45-14:00
Chairpersons: G. Coscas, France; A. Loewenstein, Israel

12:45-13:05

Is inflammation important in management of retina disease? Yes or no?
J. Ambati
, USA
13:05-13:25
What determines to retreat or not, vision or OCT?
R. Tadayoni
, France
13:25-13:45
RVO in clinical practice, steroids vs. anti-VEGF
A. Loewenstein, Israel
13:45-14:00
Management of Uveitis in 2013, are steroids a valuable option?
S. Lightman
, UK
 
 
 

Home   
Copyright © 2008 Comtecmed.com. All rights reserved.   The website was last updated on 10/27/2013 Created by    WebStudio.co.il